Hemostemix Inc. (CVE:HEM – Get Free Report) was up 27.9% on Thursday . The stock traded as high as C$0.29 and last traded at C$0.28. Approximately 1,401,717 shares were traded during trading, an increase of 100% from the average daily volume of 700,531 shares. The stock had previously closed at C$0.22.
Hemostemix Price Performance
The company has a market cap of C$27.01 million, a P/E ratio of -15.50 and a beta of 0.20. The business’s 50 day moving average price is C$0.11 and its 200-day moving average price is C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Manufacturing Stocks Investing
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- What Are the FAANG Stocks and Are They Good Investments?
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Why Are Stock Sectors Important to Successful Investing?
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
